Results for this period
Full year1 October 2025–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
While no milestone revenue was generated from the clinical development program, selling, general and administrative expenses increased, including a 39.6% increase in research and development expenses.
There is a description of events and other matters related to the going concern assumption. Although recurring operating losses and negative operating cash flow constitute events and other matters giving rise to significant doubt, the Company recognizes that there is no material uncertainty regarding the going concern assumption. No applicable matter is stated in the notes to the financial statements.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 October 2025–30 September 2026 |
| Net Sales | ¥518 million (YoY -23.4%) |
| Operating profit | ¥-1,119 million |
| Ordinary income | ¥-1,088 million |
| Profit attributable to owners of the parent | ¥-1,183 million |
| Net income per share | -¥32.03 |
| Operating Margin | △215.8％ |
| Equity ratio | End of the current fiscal period 75.4 / End of previous period 87.6 |
| Total assets | ¥2,047 million |
| Net assets | ¥1,567 million |
| Cash flows from operating activities | ¥-1,012 million |
| Cash flows from investing activities | ¥-1,205 million |
| Cash flows from financing activities | ¥25 million |
| Cash and cash equivalents at end of period | ¥741 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Note Not stated because a reasonable full-year earnings forecast cannot be calculated. |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0％） |
| Impairment loss | ¥92,129 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal of non-current assets ¥99 thousand, Impairment loss ¥92,129 thousand |
| Disclosure regarding the going concern assumption | There is a description of events and other matters related to the going concern assumption. Although recurring operating losses and negative operating cash flow constitute events and other matters giving rise to significant doubt, the Company recognizes that there is no material uncertainty regarding the going concern assumption. No applicable matter is stated in the notes to the financial statements. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Yes (for institutional investors, analysts and general investors) |
| Issued Shares at Period-End | 37,039,000 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | While no milestone revenue was generated from the clinical development program, selling, general and administrative expenses increased, including a 39.6% increase in research and development expenses. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the lack of milestone revenue from the clinical development program, selling, general and administrative expenses increased 22.2%, including a 39.6% increase in research and development expenses.